Lymphatic Malformations Pipeline Insight

DelveInsight’s, “Lymphatic Malformations– Pipeline Insight, 2022,” report provides comprehensive insights about 4+ companies and 4+ pipeline drugs in Lymphatic Malformations Pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

  • Global coverage

Lymphatic Malformations Understanding

Lymphatic Malformations: Overview

Lymphatic malformations are rare, non-malignant masses consisting of fluid-filled channels or spaces thought to be caused by the abnormal development of the lymphatic system. In lymphatic malformations, movement of lymphatic fluid into veins is slow or decreased. This causes extra fluid to collect and to enlarge the lymphatic channels. This results in swelling of the affected area. These malformations are usually apparent at birth or by two years of age. Lymphatic malformations can affect any area of the body (except the brain), but most commonly affect the head and neck. e. Lymphatic malformations, regardless of size, can potentially cause functional impairment of nearby structures or organs and disfigurement of affected areas. Lymphatic malformations have variable appearances. Depending on the size of the abnormal lymphatic channels, they are considered macrocystic, microcystic or a combination of both.


"Lymphatic Malformations- Pipeline Insight, 2022" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Lymphatic Malformations pipeline landscape is provided which includes the disease overview and Lymphatic Malformations treatment guidelines. The assessment part of the report embraces, in depth Lymphatic Malformations commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Lymphatic Malformations collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Lymphatic MalformationsR&D. The therapies under development are focused on novel approaches to treat/improve Lymphatic Malformations.

Lymphatic Malformations Emerging Drugs Chapters

This segment of the Lymphatic Malformations Report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.


Lymphatic Malformations Emerging Drugs


TARA-002: Protara Therapeutics

TARA-002 is an investigational cell therapy in development for the treatment of lymphatic malformations (LMs) and non-muscle invasive bladder cancer (NMIBC). When TARA-002 is administered, it is hypothesized that innate and adaptive immune cells within the cyst or tumor are activated and produce a strong immune cascade.TARA-002 has been Granted Orphan Drug and Fast Track Designations by the U.S. FDA. It is currently in phase II stage of development for Lymphatic malformations.


VT30: Vanthera

Venthera is developing VT30 topical gel intended to treat Venous and lymphatic malformations . In the third quarter of 2020, Venthera has initiated a first in human phase 1/2 trial of topical VT30 in patients with Venous and lymphatic malformations.

Further product details are provided in the report……..

Lymphatic Malformations: Therapeutic Assessment

This segment of the report provides insights about the different Lymphatic Malformations drugs segregated based on following parameters that define the scope of the report, such as:

  • Major Players in Lymphatic Malformations

There are approx. 4+ key companies which are developing the therapies for Lymphatic Malformations. The companies which have their Lymphatic Malformations drug candidates in the most advanced stage, i.e. phase II include, Protara Therapeutics.

Phases

DelveInsight’s report covers around 4+ products under different phases of clinical development like

  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration


Lymphatic Malformations pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Oral
  • Intravenous
  • Subcutaneous
  • Topical.
  • Molecule Type


Products have been categorized under various Molecule types such as

  • Peptides
  • Small molecule
  • Gene therapy
  • Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Lymphatic Malformations: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Lymphatic Malformations therapeutic drugs key players involved in developing key drugs.


Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Lymphatic Malformations drugs.

Lymphatic Malformations Report Insights

  • Lymphatic Malformations Pipeline Analysis
  • Therapeutic Assessment
  • Unmet Needs
  • Impact of Drugs

Lymphatic Malformations Report Assessment

  • Pipeline Product Profiles
  • Therapeutic Assessment
  • Pipeline Assessment
  • Inactive drugs assessment
  • Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

  • How many companies are developing Lymphatic Malformations drugs?
  • How many Lymphatic Malformations drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Lymphatic Malformations?
  • What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Lymphatic Malformations therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Lymphatic Malformations and their status?
  • What are the key designations that have been granted to the emerging drugs?



Introduction

Executive Summary

Lymphatic Malformations: Overview

  • Causes
  • Mechanism of Action
  • Signs and Symptoms
  • Diagnosis
  • Disease Management

Pipeline Therapeutics

  • Comparative Analysis

Therapeutic Assessment

  • Assessment by Product Type
  • Assessment by Stage and Product Type
  • Assessment by Route of Administration
  • Assessment by Stage and Route of Administration
  • Assessment by Molecule Type
  • Assessment by Stage and Molecule Type

Lymphatic Malformations– DelveInsight’s Analytical Perspective

In-depth Commercial Assessment

  • Lymphatic Malformations companies’ collaborations, Licensing, Acquisition -Deal Value Trends

Lymphatic Malformations Collaboration Deals

  • Company-Company Collaborations (Licensing / Partnering) Analysis
  • Company-University Collaborations (Licensing / Partnering) Analysis

Late Stage Products (Phase III)

  • Comparative Analysis

Drug Name: Company Name

  • Product Description
  • Research and Development
  • Product Development Activities

Drug profiles in the detailed report…..

Mid Stage Products (Phase II)

  • Comparative Analysis

TARA-002: Protara Therapeutics

  • Product Description
  • Research and Development
  • Product Development Activities

Drug profiles in the detailed report…..

Early Stage Products (Phase I/II)

  • Comparative Analysis

VT30: Vanthera

  • Product Description
  • Research and Development
  • Product Development Activities

Drug profiles in the detailed report…..

Inactive Products

  • Comparative Analysis

Lymphatic Malformations Key Companies

Lymphatic Malformations Key Products

Lymphatic Malformations- Unmet Needs

Lymphatic Malformations- Market Drivers and Barriers

Lymphatic Malformations- Future Perspectives and Conclusion

Lymphatic Malformations Analyst Views

Lymphatic Malformations Key Companies

Appendix

List of Table

Table 1: Total Products for Lymphatic Malformations

Table 2: Late Stage Products

Table 3: Mid Stage Products

Table 4: Early Stage Products

Table 5: Pre-clinical & Discovery Stage Products

Table 6: Assessment by Product Type

Table 7: Assessment by Stage and Product Type

Table 8: Assessment by Route of Administration

Table 9: Assessment by Stage and Route of Administration

Table 10: Assessment by Molecule Type

Table 11: Assessment by Stage and Molecule Type

Table 12: Inactive Products

List of Figures

Figure 1: Total Products for Lymphatic Malformations

Figure 2: Late Stage Products

Figure 3: Mid Stage Products

Figure 4: Early Stage Products

Figure 5: Preclinical and Discovery Stage Products

Figure 6: Assessment by Product Type

Figure 7: Assessment by Stage and Product Type

Figure 8: Assessment by Route of Administration

Figure 9: Assessment by Stage and Route of Administration

Figure 10: Assessment by Molecule Type

Figure 11: Assessment by Stage and Molecule Type

Figure 12: Inactive Products

•Protara therapeutics

•Vanthera

•Cerecor, Inc.

Forward to Friend

Need A Quote